Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
Clin. Cancer Res 2022 Jun 17;[EPub Ahead of Print], W Yin, Y Wang, Z Wu, Y Ye, L Zhou, S Xu, Y Lin, Y Du, T Yan, F Yang, J Zhang, Q Liu, J LuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.